Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of …
Abstract Background Recurrent Clostridioides difficile infection, associated with dysbiosis of
gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic …
gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic …
Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single …
Importance A safe and effective treatment for recurrentClostridioides difficileinfection (CDI) is
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …
A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent Clostridioides difficile infection
T Chopra - Expert Review of Anti-infective Therapy, 2023 - Taylor & Francis
Introduction Clostridiodes difficile infection (CDI) is a life-threatening illness that has been
labelled as an urgent threat by the Centers for Disease prevention (CDC). Areas Covered …
labelled as an urgent threat by the Centers for Disease prevention (CDC). Areas Covered …
The burden of CDI in the United States: a multifactorial challenge
P Feuerstadt, N Theriault, G Tillotson - BMC Infectious Diseases, 2023 - Springer
Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the
United States, of these around 30,000 will die. CDI carries significant burdens including …
United States, of these around 30,000 will die. CDI carries significant burdens including …
Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
C Lee, T Louie, L Bancke… - Therapeutic …, 2023 - journals.sagepub.com
Background: Microbiota-based treatments reduce the incidence of recurrent Clostridioides
difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient …
difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient …
Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile …
ER Dubberke, R Orenstein, S Khanna… - Infectious Diseases and …, 2023 - Springer
Introduction Effective treatments for recurrent Clostridioides difficile infection (rCDI) are
urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to …
urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to …
[HTML][HTML] Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study
A Boven, E Vlieghe, L Engstrand, FL Andersson… - Clinical Microbiology …, 2023 - Elsevier
Objectives Clostridioides difficile infection (CDI) is a common healthcare-associated
infection and leading cause of gastroenteritis-related mortality worldwide. However, data on …
infection and leading cause of gastroenteritis-related mortality worldwide. However, data on …
Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea,
with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic …
with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic …
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
KR Reveles, M Yang, V Garcia-Horton, ML Edwards… - Advances in …, 2023 - Springer
Introduction Up to 35% of patients with a first episode of Clostridioides difficile infection (CDI)
develop recurrent CDI (rCDI), and of those, up to 65% experience multiple recurrences. A …
develop recurrent CDI (rCDI), and of those, up to 65% experience multiple recurrences. A …
Clostridioides difficile in Foods with Animal Origins; Prevalence, Toxigenic Genes, Ribotyping Profile, and Antimicrobial Resistance
Clostridioides difficile is an important nosocomial pathogen and is considered as a reason of
diarrhea and gastrointestinal infections. As a majority of community‐originated C. difficile …
diarrhea and gastrointestinal infections. As a majority of community‐originated C. difficile …